Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
10 févr. 2022 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
18 janv. 2022 01h00 HE
|
Molecular Partners
Agreement grants global rights of ensovibep to Novartis, who will lead further development and commercialization of the programFinancial terms include milestone payment of CHF150 million to Molecular...
Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange Regulations
13 janv. 2022 17h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland & CONCORD, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage...
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
10 janv. 2022 01h17 HE
|
Molecular Partners
Topline results from the randomized, placebo-controlled EMPATHY Part A study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep, a DARPin antiviral therapeutic...
Molecular Partners to Present at Upcoming Healthcare Investor Conferences
05 janv. 2022 16h05 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners to Host Oncology Day (Virtual)
15 déc. 2021 01h00 HE
|
Molecular Partners
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of...
Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for Oncology
14 déc. 2021 01h00 HE
|
Molecular Partners
Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancerNovartis...
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical Studies
12 déc. 2021 16h00 HE
|
Molecular Partners
Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency...
Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in December
09 déc. 2021 01h00 HE
|
Molecular Partners
Program overview and study design for MP0317 to be presented at ESMO Immuno-OncologyPreclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASHOncology R&D Day to...
Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021
06 déc. 2021 01h00 HE
|
Molecular Partners
First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical...